Unity Biotechnology Inc Expected To Post A Loss Of 26 Cents A Share: Earnings Preview

Unity Biotechnology

06/05/2022 18:44

* UNITY Biotechnology Inc  UBX.OQ   UBX.O  is expected
to show no
change in quarterly revenue when it reports  results on May 9
(estimated). 
    * ​Refinitiv's mean analyst estimate for UNITY Biotechnology
Inc
is for a loss of 26 cents per share. For the same quarter last
year, the company reported a loss of 29 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 3.7%
in the last three months. ​
    * Wall Street's median 12-month price target for UNITY
Biotechnology Inc is $6​, above​ its last closing price
of $0.86. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.31       -0.38      -0.18     Beat    53.2
 Sep. 30 2021  -0.38       -0.37      -0.30     Beat    19.2
 Jun. 30 2021  -0.29       -0.31      -0.32     Missed  -4.1​
 Mar. 31 2021  -0.37       -0.38      -0.29     Beat    23.6
 ​​Dec.                    -0.47      -0.37     Beat    21.5
 31 2020                                                
 Sep. 30 2020  -0.49       -0.49      -0.52     Missed  -5.9​
 Jun. 30 2020  -0.51       -0.51      -0.38     Beat    25.7
 Mar. 31 2020  -0.51       -0.51      -0.54     Missed  -6.6
 This summary was machine generated May 6 at 17:44 GMT.  All
figures in US dollars  unless otherwise stated